Compass Therapeutics Inc. stocks have been trading up by 8.25 percent following promising oncology trial results boosting investor optimism.
Click Here for a Millionaire's POV on Trading CMPX
SUBSCRIBE FOR ALERTSJOIN 50,000+ ACTIVE TRADERS
What Traders Need To Know
- Compass Therapeutics will host an 2026/04/27 webcast to share topline secondary endpoint data from its Phase 2/3 COMPANION-002 trial in advanced biliary tract cancer.
- The COMPANION-002 study tests tovecimig with paclitaxel, targeting a hard-to-treat cancer where any meaningful signal can move CMPX sharply.
- The upcoming secondary endpoint readout signals the trial is advanced enough to provide additional efficacy and safety clarity to the market.
- Recent trading shows CMPX breaking higher after a tight range, suggesting traders are already positioning ahead of the webcast.
Weekly Update Apr 20 – Apr 24, 2026: On Saturday, April 25, 2026 Compass Therapeutics Inc. stock [NASDAQ: CMPX] is trending up by 8.25%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Healthcare industry expert:
Analyst sentiment – positive
Compass Therapeutics remains an early‑stage oncology developer with no commercial revenue and structurally negative profitability (ROE roughly -41%, ROA about -37%). The balance sheet is its main asset: ~$209M in cash and short‑term investments, minimal leverage (total debt-to-equity 0.05, current and quick ratios ~15x), and EV of ~$707M imply substantial runway despite FY25 operating cash burn of ~$13M in Q4. Book value per share of $1.09 versus price-to-book of 4.8 reflects high embedded pipeline expectations.
Technically, CMPX has broken out from a tight 5.20–5.40 consolidation, closing the week at 5.64 after a wide‑range 5.03–5.85 session, confirming an emerging bullish trend on elevated volume. Intraday 5‑minute candles show aggressive dip‑buying near 5.20–5.30 and repeated rejection just under 5.85, establishing 5.20 as near‑term support and 5.80–5.90 as resistance. A tactical trading level is a buy zone at 5.25–5.35 with a stop below 5.00 targeting a move toward 6.20.
More Breaking News
- CAST Stock Slides As Traders Eye Cash Burn And Volatility
- CMPS Soars As Compass Pathways Rides Psychedelic Policy Wave
- Pitney Bowes (PBI) Rallies After Citizens Hikes Price Target
- NVTS Stock Soars As Traders Bet On Power Chip Pivot
The upcoming April 27, 2026 webcast for topline secondary endpoint data in COMPANION‑002 (tovecimig + paclitaxel in advanced biliary tract cancer) is a binary catalyst that will drive the next major repricing. Relative to Healthcare and Biotech benchmarks, CMPX offers higher clinical upside but also outsized trial‑specific risk and no diversification. My verdict is cautiously constructive: accumulate on dips with technical support at 5.20, key support at 4.75, resistance at 6.50, and a 6–12 month risk‑adjusted target of $7.
Quick Financial Overview
Compass Therapeutics Inc. sits in classic development-stage biotech territory: meaningful cash, heavy research spend, and negative earnings. The latest quarterly numbers show net income of about -$15.7M and EBITDA near -$19.8M, which lines up with a clinical company still in build mode rather than a revenue story. For traders, that means price tends to move more on data and headlines than on traditional earnings metrics.
On the balance sheet, Compass Therapeutics Inc. looks relatively strong for a small-cap biotech. Total assets are about $219.6M, with cash, cash equivalents, and short-term investments above $200M, and total liabilities around $22.8M. A current ratio near 15 and very low debt-to-equity of roughly 0.05 show CMPX is not under immediate balance-sheet pressure, which reduces near-term financing risk but does not remove it.
Key ratios confirm the picture: returns on equity and assets are deeply negative, reflecting ongoing losses, while price-to-book near 4.8 and enterprise value around $707M tell traders the market is already pricing in meaningful pipeline optionality. On the tape, the weekly chart shows CMPX grinding sideways near the mid-$5 area before a strong push from a $5.03 open to roughly $5.64 on 2026/04/24, a notable breakout from the prior tight range. Intraday, a 5-minute candle that flushed to about $4.90 before reclaiming above $5.00 and then pressing toward $5.49 shows dip buyers stepping in aggressively, a sign of growing speculative interest ahead of the data webcast.
Conclusion
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.